BRAF and pulmonary arterial hypertension: Also, the selective VEGFR blocker cabozatinib tended to exacerbate pulmonary hypertension (RV hypertrophy), unlike non-selective VEFGR blockers that additionally target PDGFR-β or FGFR 1 (regorafenib), PDGFR-β or c-KIT (sunitinib), or b-RAF, c-KIT, or PDGFR-β (sorafenib) (Table 1 and Table S4, Figure 2 and Figure S2).